Groprinosin vs LL-37
Overview
Groprinosin is primarily a immune support peptide, while LL-37 is used for pain management.
This page compares Groprinosin and LL-37 across their primary use, typical dosing, reported benefits and side effects, and U.S. regulatory status. For the full monograph on either compound — mechanism of action, clinical research, and references — follow the article links.
Side-by-side comparison
| Groprinosin | LL-37 | |
|---|---|---|
| Category | Immune Support | Pain Management |
| Regulatory status (US) | Research use only | Compounding (Rx) — Apr 2026 |
| Typical dosage | 500-1000 mg | 2-5 mg |
| Frequency | three times daily | twice weekly |
| Reported benefits | Antiviral activity, immune enhancement, lymphocyte stimulation | Inflammation-related pain relief, infection-related pain support |
| Reported side effects | Possible GI upset, elevated uric acid | Generally safe |
Key differences
Primary use. Groprinosin is categorised under Immune Support, while LL-37 falls under Pain Management. Their differing categories mean they are usually chosen for different goals rather than as direct substitutes.
Regulatory status. Groprinosin: not FDA-approved; treated as a research compound. LL-37: not FDA-approved; compounding permitted with a prescription as of April 2026.
Dosing. Groprinosin is typically dosed at 500-1000 mg (three times daily). LL-37 is typically dosed at 2-5 mg (twice weekly).
Can you stack them?
Some protocols combine peptides, but stacking Groprinosin and LL-37 has not been validated for safety or efficacy in controlled trials. Combining compounds can change their effects and risks. Nothing here is medical advice — consult a qualified healthcare provider before starting or combining any protocol.
Frequently asked questions
- What is the difference between Groprinosin and LL-37?
- Groprinosin is primarily a immune support peptide, while LL-37 is used for pain management. Groprinosin is not FDA-approved; generally classified as a research compound, whereas LL-37 is not FDA-approved; compounding permitted with a prescription (as of April 2026).
- What is Groprinosin used for?
- Antiviral immune booster.
- What is LL-37 used for?
- Inflammatory pain modulation.
- Can you take Groprinosin and LL-37 together?
- Some users combine peptides within a single protocol, but stacking Groprinosin and LL-37 has not been established as safe or effective in controlled trials. Neither this comparison nor PeptideSciences101 is medical advice — consult a qualified healthcare provider before combining any compounds.
- Is Groprinosin or LL-37 FDA-approved?
- Groprinosin is not FDA-approved; generally classified as a research compound. LL-37 is not FDA-approved; compounding permitted with a prescription (as of April 2026).
Read the full articles
- Groprinosin — full monograph: mechanism, research, dosing & references
- LL-37 — full monograph: mechanism, research, dosing & references